First Horizon Advisors, Inc. Chemo Centryx, Inc. Transaction History

First Horizon Advisors, Inc.

$3.58 Billion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 09, 2022	SELL	$22.17 - $51.8 $3,835 - $8,961	-173 Reduced 41.49%	244 $12,000
Q2 2022 Aug 02, 2022	BUY	$15.36 - $27.51 $6,405 - $11,471	417 New	417 $10,000
Q1 2022 May 10, 2022	SELL	$22.22 - $39.12 $4,399 - $7,745	-198 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$18.38 - $40.5 $3,639 - $8,019	198 New	198 $7,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.